Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis. (Q53128686)

From Wikidata

Jump to navigation Jump to search

scientific article published on 11 June 2012

Language	Label	Description	Also known as
English	Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis.	scientific article published on 11 June 2012

Statements

scholarly article

1 reference

Europe PubMed Central

11 May 2018

http://europepmc.org/abstract/MED/22689179

Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis. (English)

1 reference

Europe PubMed Central

11 May 2018

http://europepmc.org/abstract/MED/22689179

1 reference

based on heuristic

inferred from title

author name string

Y Y Janjigian

1

1 reference

Europe PubMed Central

11 May 2018

http://europepmc.org/abstract/MED/22689179

D Werner

2

1 reference

Europe PubMed Central

11 May 2018

http://europepmc.org/abstract/MED/22689179

C Pauligk

3

1 reference

Europe PubMed Central

11 May 2018

http://europepmc.org/abstract/MED/22689179

K Steinmetz

4

1 reference

Europe PubMed Central

11 May 2018

http://europepmc.org/abstract/MED/22689179

D P Kelsen

5

1 reference

Europe PubMed Central

11 May 2018

http://europepmc.org/abstract/MED/22689179

E Jäger

6

1 reference

Europe PubMed Central

11 May 2018

http://europepmc.org/abstract/MED/22689179

H-M Altmannsberger

7

1 reference

Europe PubMed Central

11 May 2018

http://europepmc.org/abstract/MED/22689179

E Robinson

8

1 reference

Europe PubMed Central

11 May 2018

http://europepmc.org/abstract/MED/22689179

L J Tafe

9

1 reference

Europe PubMed Central

11 May 2018

http://europepmc.org/abstract/MED/22689179

L H Tang

10

1 reference

Europe PubMed Central

11 May 2018

http://europepmc.org/abstract/MED/22689179

M A Shah

11

1 reference

Europe PubMed Central

11 May 2018

http://europepmc.org/abstract/MED/22689179

S-E Al-Batran

12

1 reference

Europe PubMed Central

11 May 2018

http://europepmc.org/abstract/MED/22689179

publication date

11 June 2012

1 reference

Europe PubMed Central

11 May 2018

http://europepmc.org/abstract/MED/22689179

Annals of Oncology

1 reference

Europe PubMed Central

11 May 2018

http://europepmc.org/abstract/MED/22689179

23

1 reference

Europe PubMed Central

11 May 2018

http://europepmc.org/abstract/MED/22689179

2656-2662

1 reference

Europe PubMed Central

11 May 2018

http://europepmc.org/abstract/MED/22689179

10

1 reference

Europe PubMed Central

11 May 2018

http://europepmc.org/abstract/MED/22689179

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS104

21 January 2018

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS104

21 January 2018

Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS104

21 January 2018

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS104

21 January 2018

HER 2/neu protein expression in colorectal cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS104

21 January 2018

HER-2/neu oncogene characterization in head and neck squamous cell carcinoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS104

21 January 2018

Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS104

21 January 2018

Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS104

21 January 2018

HER-2/neu amplification is an independent prognostic factor in gastric cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS104

21 January 2018

HER-2 amplification is highly homogenous in gastric cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS104

21 January 2018

Her-2/neu gene amplification in esophageal adenocarcinoma and its influence on survival.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS104

21 January 2018

Assessment of a HER2 scoring system for gastric cancer: results from a validation study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS104

21 January 2018

HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS104

21 January 2018

Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS104

21 January 2018

Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS104

21 January 2018

Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS104

21 January 2018

HER2 expression in gastric and gastroesophageal junction adenocarcinoma in a US population: clinicopathologic analysis with proposed approach to HER2 assessment.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS104

21 January 2018

Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS104

21 January 2018

Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS104

21 January 2018

Prognostic significance of expression patterns of c-erbB-2, p53, p16INK4A, p27KIP1, cyclin D1 and epidermal growth factor receptor in oesophageal adenocarcinoma: a tissue microarray study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS104

21 January 2018

Early Gastric Cancer in Young, Asymptomatic Carriers of Germ-Line E-Cadherin Mutations

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS104

21 January 2018

Identifiers

10.1093/ANNONC/MDS104

1 reference

Europe PubMed Central

11 May 2018

http://europepmc.org/abstract/MED/22689179

1 reference

Europe PubMed Central

11 May 2018

http://europepmc.org/abstract/MED/22689179

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53128686&oldid=1242704857"